Principal Financial Group Inc Akero Therapeutics, Inc. Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$18.31 - $24.62 $78,220 - $105,176	-4,272 Reduced 31.03%	9,494 $222,000
Q1 2024 Apr 29, 2024	BUY	$17.76 - $31.18 $32,998 - $57,932	1,858 Added 15.6%	13,766 $347,000
Q4 2023 Feb 07, 2024	BUY	$11.38 - $50.33 $2,082 - $9,210	183 Added 1.56%	11,908 $278,000
Q3 2023 Nov 02, 2023	BUY	$41.19 - $52.25 $13,963 - $17,712	339 Added 2.98%	11,725 $593,000
Q2 2023 Aug 07, 2023	BUY	$36.89 - $56.88 $26,782 - $41,294	726 Added 6.81%	11,386 $531,000
Q1 2023 May 09, 2023	BUY	$37.27 - $50.24 $48,935 - $65,965	1,313 Added 14.05%	10,660 $407,000
Q4 2022 Feb 09, 2023	BUY	$33.44 - $54.8 $76,477 - $125,327	2,287 Added 32.39%	9,347 $512,000
Q3 2022 Nov 09, 2022	BUY	$10.15 - $34.05 $71,659 - $240,392	7,060 New	7,060 $241,000
Q1 2021 May 10, 2021	BUY	$24.04 - $34.19 $185,324 - $263,570	7,709 New	7,709 $224,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.